Behzad Aghazadeh Net Worth

The estimated Net Worth of Behzad Aghazadeh is at least $1.41 Billion dollars as of 14 November 2017. Behzad Aghazadeh owns over 1,325,000 units of Immunomedics stock worth over $1,411,423,543 and over the last 7 years Behzad sold IMMU stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Behzad Aghazadeh IMMU stock SEC Form 4 insiders trading

Behzad has made over 1 trades of the Immunomedics stock since 2017, according to the Form 4 filled with the SEC. Most recently Behzad bought 1,325,000 units of IMMU stock worth $13,872,750 on 14 November 2017.

The largest trade Behzad's ever made was buying 1,325,000 units of Immunomedics stock on 14 November 2017 worth over $13,872,750. On average, Behzad trades about 1,325,000 units every 0 days since 2017. As of 14 November 2017 Behzad still owns at least 16,064,461 units of Immunomedics stock.

You can see the complete history of Behzad Aghazadeh stock trades at the bottom of the page.

What's Behzad Aghazadeh's mailing address?

Behzad's mailing address filed with the SEC is C/O VENBIO SELECT ADVISOR LLC, 120 W. 45TH STREET, 28TH FLOOR, NEW YORK, NY, 10036.

Insiders trading at Immunomedics

Over the last 21 years, insiders at Immunomedics have traded over $5,318,095 worth of Immunomedics stock and bought 12,330,539 units worth $195,802,181 . The most active insiders traders include Capital Advisors Llc Aghaza..., David M Goldenberg, and Cynthia L Goldenberg. On average, Immunomedics executives and independent directors trade stock every 105 days with the average trade being worth of $27,159,459. The most recent stock trade was executed by Barbara Gayle Duncan on 14 September 2020, trading 2,500 units of IMMU stock currently worth $42,400.

What does Immunomedics do?

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Complete history of Behzad Aghazadeh stock trades at Immunomedics

Immunomedics executives and stock owners

Immunomedics executives and other stock owners filed with the SEC include:

• Behzad Avoro Capital Adviso...,
  
• Geoffrey F Cox,
  Director
• Robert Forrester,
  Director
• Jason Aryeh,
  Director
• Harout Semerjian,
  President and CEO
• Bob Oliver,
  Director
• Marvin Jaffe,
  Director
• Michael F. Pehl,
  President and CEO
• Capital Advisors Llc Aghaza...,
  
• Peter Barton Hutt,
  Director
• Scott A Canute,
  Director
• Khalid Islam,
  Director
• Michael Garone,
  CHIEF FINANCIAL OFFICER
• Brian A Markison,
  Director
• Behzad Aghazadeh,
  Director
• Select Advisor Llc Ven Bio,
  Director
• Robert Iannone,
  CHIEF MEDICAL OFFICER
• William Fricker,
  Principal Accounting Officer
• Morris Rosenberg,
  Chief Technology Officer
• Charles M Baum,
  Director
• Bryan Ball,
  Chief Quality Officer
• Barbara Gayle Duncan,
  Director
• Kurt J. Andrews,
  Chief Human Resources Officer
• Ivan D Horak,
  EVP R&D & Ch. Scientific Off.
• Cynthia L Goldenberg,
  President and CEO
• Richard R Pivirotto,
  Director
• Don C Stark,
  Director
• Mary E Paetzold,
  Director
• Arthur S Kirsch,
  Director
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Richard L. Sherman,
  Director
• David M Goldenberg,
  Chairman & Ch. Strategic Off.
• Marcella Lo Castro,
  Director
• Edward T Wolynic,
  Director
• Morton Coleman,
  Director
• Gerard G Gorman,
  VP of Finance & CFO
• Kenneth J Zuerblis,
  Director
• Lorettta M Itri,
  Chief Medical Officer
• Robert Azelby,
  Director
• Usama Malik,
  Chief Fin. & Business Officer
• Brendan Delaney,
  Chief Commercial Officer
• Jared Freedberg,
  Gen. Counsel & Corp. Secretary